ScreenerHero

TRAWTraws Pharma Inc. Common Stock

NAS · US · Healthcare · Biotechnology · trawspharma.com
0.5300USD-1.85%Mkt Cap: 8.15M $P/E: —

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and CO…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.15M $
Enterprise Value5.52M $
Revenue (TTM)2.73M $
Gross Profit2.73M $
Net Income (TTM)9.17M $
Revenue/Share0.2990 USD
Last Price0.5300 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.28
PEG—
EV/EBITDA-0.28
EV/Revenue2.02
P/S2.92
P/B-0.99
EPS (TTM)-1.77
EPS (Forward)-1.88
52W Range
0.43014% of range3.270
52W High3.270 USD
52W Low0.4301 USD
Profitability
Gross Margin100.00%
Oper. Margin-717.82%
EBITDA Margin0.00%
Profit Margin328.67%
ROE-1457.87%
ROA86.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.18M $
CapEx (TTM)2.58M $
FCF Margin-378.60%
FCF Yield-127.04%
Net Debt-3.13M $
Net Debt/EBITDA0.16
Balance Sheet
Debt/Equity—
Current Ratio0.43
Quick Ratio0.36
Book Value/Sh-0.5230 USD
Cash/Share0.2070 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateSep 23, 2024
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.000 USD
Upside (mean)+88.7%
Target Range1.000 USD – 1.000 USD
# Analysts1
Ownership
Shares Out.15.37M
Float11.74M
Insiders5.38%
Institutions49.55%
Short Interest
Short Ratio4.2d
Short % Float4.85%
Short % Out.4.12%
Shares Short627.17K
Short (prev mo.)980.14K
Technical
SMA 500.6842 (-22.5%)
SMA 2001.514 (-65.0%)
Beta1.56
S&P 52W Chg18.16%
Avg Vol (30d)114.16K
Avg Vol (10d)91.67K
Technical Indicators
RSI (14)40.3
MACD-0.0486
MACD Signal-0.0690
MACD Hist.+0.0204
BB Upper0.6018 USD
BB Middle0.5229 USD
BB Lower0.4441 USD
BB Width30.14%
ATR (14)0.0483 USD
Vol Ratio (20d)2.10x